top of page
Danone S.A. (DANOY) Financial Performance Review

Danone S.A. (DANOY) Financial Performance Review

Danone S.A. reported earnings per share (EPS) of $0.39 for the last quarter, missing the consensus estimate of $0.42. Revenue, however, was robust at $15.1 billion, surpassing the expected $7.15 billion, reflecting strong sales performance. The company achieved a recurring operating margin of 13.2%, up 49 basis points, driven by operational efficiencies, with free cash flow reaching €1.2 billion.


Danone S.A. (PNK:DANOY), a global leader in the food and beverage industry, operates in Essential Dairy & Plant-Based products, Waters, and Specialized Nutrition. With 2024 sales of €27.4 billion and products sold in over 120 markets, Danone focuses on healthier, sustainable eating and drinking habits.First Half 2025 Highlights

 

In the first half of 2025, Danone recorded sales of €13.7 billion, a 4.2% like-for-like increase, fueled by a 2.6% volume/mix growth and a 1.7% price increase. The recurring operating margin rose to 13.2%, supported by operational improvements. Free cash flow stood at €1.2 billion, underscoring financial resilience.

 

The price-to-earnings (P/E) ratio is approximately 42.71, indicating strong investor confidence. Under CEO Antoine de Saint-Affrique, Danone continues to prioritize its health-focused portfolio, including high-protein products, medical nutrition, Alpro, and Aptamil. The company expanded its medical nutrition segment with the acquisition of Kate Farms in the US, reinforcing its commitment to innovation despite market volatility.


Danone reaffirmed its 2025 guidance, projecting like-for-like sales growth of 3% to 5%, with recurring operating income expected to outpace sales growth. The current ratio of 0.93 signals potential liquidity challenges, with current assets slightly below current liabilities. Danone’s strong revenue performance and operational improvements highlight its resilience, though EPS misses and liquidity concerns warrant attention. The company’s strategic focus on health-oriented products positions it well for sustained growth in a competitive market.

Want to know when to buy this stock? Download the Stocks 2 Buy app or try the Web version

Group 82_edited.png

Forecast your chosen stock price with the Stock Sentiment Map

Comments

Share Your ThoughtsBe the first to write a comment.
Copy of Logo circular simple negro.png
bottom of page